Validation of [ 18 F]FLT as a perfusion-independent imaging biomarker of tumour response in EGFR-mutated NSCLC patients undergoing treatment with an EGFR tyrosine kinase inhibitor

ConclusionThe present study suggests that [18F]FLT might be a perfusion-independent PET tracer for measuring tumour response as parametric changes in [18F]FLT uptake occurred independent from changes in perfusion.Trial registrationNederlands Trial Register (NTR),NTR3557. Registered 2 August 2012
Source: EJNMMI Research - Category: Radiology Source Type: research